Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

284Citations
Citations of this article
186Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal tissues. Immunotherapeutic targeting of EGFRvIII could eliminate neoplastic cells more precisely but may be inhibited by concurrent myelosuppressive chemotherapy like temozolomide (TMZ), which produces a survival benefit in GBM. A phase II, multicenter trial was undertaken to assess the immunogenicity of an experimental EGFRvIII-targeted peptide vaccine in patients with GBM undergoing treatment with serial cycles of standard-dose (STD) (200 mg/m2 per 5 days) or dose-intensified (DI) TMZ (100 mg/m2 per 21 days). All patients receiving STD TMZ exhibited at least a transient grade 2 lymphopenia, whereas those receiving DI TMZ exhibited a sustained grade 3 lymphopenia (<500 cells/μL). CD3+ T-cell (P 5 .005) and B-cell (P 5 .004) counts were reduced significantly only in the DI cohort. Patients in the DI cohort had an increase in the proportion of immunosuppressive regulatory T cells (TReg; P 5 .008). EGFRvIII-specific immune responses developed in all patients treated with either regimen, but the DI TMZ regimen produced humoral (P 5 .037) and delayed-type hypersensitivity responses (P 5 .036) of greater magnitude. EGFRvIIIexpressing tumor cells were also eradicated in nearly all patients (91.6%; CI95: 64.0%-99.8%; P < .0001). The median progression-free survival (15.2 months; CI95: 11.0-18.5 months; hazard ratio [HR] 5 0.35; P 5 .024) and overall survival (23.6 months; CI95: 18.5-33.1 months; HR 5 0.23; P 5 .019) exceeded those of historical controls matched for entry criteria and adjusted for known prognostic factors. EGFRvIIItargeted vaccination induces patient immune responses despite therapeutic TMZ-induced lymphopenia and eliminates EGFRvIII-expressing tumor cells without autoimmunity. © The Author(s) 2011.

Cite

CITATION STYLE

APA

Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., … Heimberger, A. B. (2011). Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology, 13(3), 324–333. https://doi.org/10.1093/neuonc/noq157

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free